Benchmark Starts Reviva Pharmaceuticals (RVPH) at Speculative Buy, 'A Potentially Best-In-Class Treatment for Schizophrenia'
Tweet Send to a Friend
(Updated - June 8, 2023 6:13 AM EDT)
Benchmark analyst Bruce Jackson initiates coverage on Reviva Pharmaceuticals (NASDAQ: RVPH) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Benchmark analyst Bruce Jackson initiates coverage on Reviva Pharmaceuticals (NASDAQ: RVPH) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
